Related references
Note: Only part of the references are listed.Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Heather A. Wakelee et al.
LANCET ONCOLOGY (2017)
Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels
M. Cobo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Lucio Buffoni et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan F. Vansteenkiste et al.
LANCET ONCOLOGY (2016)
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A Phase 2 Cooperative Group Adjuvant Trial Using a Biomarker-Based Decision Algorithm in Patients With Stage I Non-Small Cell Lung Cancer (SWOG-0720, NCT00792701)
Gerold Bepler et al.
CANCER (2014)
Customized Adjuvant Phase II Trial in Patients With Non-Small-Cell Lung Cancer: IFCT-0801 TASTE
Marie Wislez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer
Gerold Bepler et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer Implications for Therapy
Martin K. H. Maus et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small-Cell Lung Cancer Treated with Pemetrexed
Daniel C. Christoph et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer
Luc Friboulet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis
George R. Simon et al.
CANCER (2012)
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
Charles A. Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
A. Auperin et al.
LANCET (2010)
Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non-Small-Cell Lung Cancer
Craig Reynolds et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer
Zhong Zheng et al.
CANCER (2008)
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors
Paolo Ceppi et al.
CLINICAL CANCER RESEARCH (2008)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer
Rafael Rosell et al.
PLOS ONE (2007)
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression:: A phase III trial in non-small-cell lung cancer
Manuel Cobo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer
Zhong Zheng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase
Paolo Ceppi et al.
CANCER (2006)
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer
GV Scagliotti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
Y Shirota et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
